Qureight

Qureight is an AI powered imaging contract research organization serving biopharma sponsors running clinical trials in lung and heart disease. It delivers its services through a proprietary data and imaging curation platform that handles image management, quality control, central reads and analysis, and its stated aim is to bring new therapies to market faster. The company offers three main products. Global imaging CRO services cover trial workflow tools, rapid onboarding of trial sites and participant evaluation. AI powered endpoints and analytics are deep learning imaging biomarkers, named Lung8, Air8, Fibr8, Glass8 and Vascul8, that are generated from standard of care inspiratory CT scans and are built to track treatment response, predict disease progression and report baseline disease severity. Data science products include synthetic control arms, cohort enrichment and enrolled cohort reporting, built on commercial access to real world data sets. The current therapeutic areas are interstitial lung diseases, including idiopathic and progressive pulmonary fibrosis, pulmonary hypertension and bronchiectasis. The company is based in Cambridge and London in the United Kingdom, and its team combines respiratory medicine, radiology, machine learning and engineering. Qureight is an enterprise service sold to sponsors on a study by study basis. Pricing is not published, and the site invites prospective customers to make contact directly.